Alembic announces USFDA tentative approval for Selexipag for Injection, 1,800 mcg/vial
Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension
Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025
Yann d’Hervé takes over responsibility for the Health Care business at Evonik, effective July 1
The expiry date of almost all strips is rubber stamped vanish in a matter of 3 to 4 months, making the remaining tablets waste for subsequent use before expire date
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
DKSH’s Business Unit Consumer Goods further capitalizes on its position to strengthen the consumer health, nutrition, and baby care categories
Mahatma Gandhi Cancer Hospital & Research Institute has emerged as the leading provider of comprehensive cancer care in Viza
Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission
Subscribe To Our Newsletter & Stay Updated